ARF tumor suppression in the nucleolus

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 6, 2014, Pages 831-839

  Maggi, Leonard B ^a   Winkeler, Crystal L ^a   Miceli, Alexander P ^a   Apicelli, Anthony J ^a   Brady, Suzanne N ^a   Kuchenreuther, Michael J ^a   Weber, Jason D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ARF; Cell cycle; Nucleolus; P53; Ribosome

Indexed keywords

ARF PROTEIN; BMI1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; RIBOSOME RNA; PROTEIN BINDING; PROTEIN MDM2;

CANCER INHIBITION; CELL FUNCTION; CELL MATURATION; CELL STRUCTURE; GENE CONTROL; GENE DELETION; GENE EXPRESSION REGULATION; GENE LOCUS; GERM CELL; HUMAN; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; RNA PROCESSING; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSCRIPTION REGULATION; TRANSLATION INITIATION; CELL CYCLE CHECKPOINT; GENETICS; METABOLISM; RIBOSOME;

CELL CYCLE CHECKPOINTS; CELL NUCLEOLUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; RIBOSOMES; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897047751     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.01.016     Document Type: Review

References (162)

1. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995, 83:993-1000.
2. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000, 60:3689-3695.
3. Pasmant E., Laurendeau I., Heron D., Vidaud M., Vidaud D., Bieche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 2007, 67:3963-3969.
4. Kim S.H., Mitchell M., Fujii H., Llanos S., Peters G. Absence of p16INK4a and truncation of ARF tumor suppressors in chickens. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:211-216.
5. Quelle D.E., Cheng M., Ashmun R.A., Sherr C.J. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:669-673.
6. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K.H., Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998, 17:5001-5014.
7. Weber J.D., Jeffers J.R., Rehg J.E., Randle D.H., Lozano G., Roussel M.F., Sherr C.J., Zambetti G.P. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 2000, 14:2358-2365.
8. den Besten W., Kuo M.L., Tago K., Williams R.T., Sherr C.J. Ubiquitination of, and sumoylation by, the Arf tumor suppressor. Isr. Med. Assoc. J. 2006, 8:249-251.
9. Gil J., Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 2006, 7:667-677.
10. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
11. Schwartz Y.B., Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat. Rev. Genet. 2007, 8:9-22.
12. Levine S.S., King I.F., Kingston R.E. Division of labor in polycomb group repression. Trends Biochem. Sci. 2004, 29:478-485.
13. Bracken A.P., Kleine-Kohlbrecher D., Dietrich N., Pasini D., Gargiulo G., Beekman C., Theilgaard-Monch K., Minucci S., Porse B.T., Marine J.C., Hansen K.H., Helin K. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 2007, 21:525-530.
14. Haupt Y., Alexander W.S., Barri G., Klinken S.P., Adams J.M. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991, 65:753-763.
15. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65:737-752.
16. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
17. Jacobs J.J., Scheijen B., Voncken J.W., Kieboom K., Berns A., van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 1999, 13:2678-2690.
18. Gil J., Bernard D., Martinez D., Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat. Cell Biol. 2004, 6:67-72.
19. Dietrich N., Bracken A.P., Trinh E., Schjerling C.K., Koseki H., Rappsilber J., Helin K., Hansen K.H. Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. EMBO J. 2007, 26:1637-1648.
20. Zeng Y., Kotake Y., Pei X.H., Smith M.D., Xiong Y. p53 binds to and is required for the repression of Arf tumor suppressor by HDAC and polycomb. Cancer Res. 2011, 71:2781-2792.
21. Barradas M., Anderton E., Acosta J.C., Li S., Banito A., Rodriguez-Niedenfuhr M., Maertens G., Banck M., Zhou M.M., Walsh M.J., Peters G., Gil J. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 2009, 23:1177-1182.
22. Young N.P., Jacks T. Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10184-10189.
23. Rowland B.D., Denissov S.G., Douma S., Stunnenberg H.G., Bernards R., Peeper D.S. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell 2002, 2:55-65.
24. Aslanian A., Iaquinta P.J., Verona R., Lees J.A. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev. 2004, 18:1413-1422.
25. Jacobs J.J., Keblusek P., Robanus-Maandag E., Kristel P., Lingbeek M., Nederlof P.M., van Welsem T., van de Vijver M.J., Koh E.Y., Daley G.Q., van Lohuizen M. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet. 2000, 26:291-299.
26. Maeda T., Hobbs R.M., Merghoub T., Guernah I., Zelent A., Cordon-Cardo C., Teruya-Feldstein J., Pandolfi P.P. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 2005, 433:278-285.
27. Suzuki A., Sekiya S., Buscher D., Izpisua Belmonte J.C., Taniguchi H. Tbx3 controls the fate of hepatic progenitor cells in liver development by suppressing p19ARF expression. Development 2008, 135:1589-1595.
28. Sharpless N.E., Ramsey M.R., Balasubramanian P., Castrillon D.H., DePinho R.A. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 2004, 23:379-385.
29. Kamijo T., Bodner S., van de Kamp E., Randle D.H., Sherr C.J. Tumor spectrum in ARF-deficient mice. Cancer Res. 1999, 59:2217-2222.
30. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91:649-659.
31. Saporita A.J., Maggi L.B., Apicelli A.J., Weber J.D. Therapeutic targets in the ARF tumor suppressor pathway. Curr. Med. Chem. 2007, 14:1815-1827.
32. Williams R.T., Roussel M.F., Sherr C.J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6688-6693.
33. Volanakis E.J., Williams R.T., Sherr C.J. Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia. Blood 2009, 114:4451-4459.
34. Kelly-Spratt K.S., Gurley K.E., Yasui Y., Kemp C.J. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol. 2004, 2:E242.
35. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999, 13:2658-2669.
36. Chin L., Pomerantz J., DePinho R.A. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem. Sci. 1998, 23:291-296.
37. Sharpless N.E. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 2005, 576:22-38.
38. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2001, 2:731-737.
39. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 1996, 68:67-108.
40. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hovig E., Harris C.C., Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 1997, 25:151-157.
41. Gardie B., Cayuela J.M., Martini S., Sigaux F. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 1998, 91:1016-1020.
42. Rizos H., Darmanian A.P., Holland E.A., Mann G.J., Kefford R.F. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J. Biol. Chem. 2001, 276:41424-41434.
43. Rutter J.L., Goldstein A.M., Davila M.R., Tucker M.A., Struewing J.P. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. Oncogene 2003, 22:4444-4448.
44. Zhang Y., Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 1999, 3:579-591.
45. del Arroyo A.G., Peters G. The Ink4a/Arf network-cell cycle checkpoint or emergency brake?. Adv. Exp. Med. Biol. 2005, 570:227-247.
46. Randerson-Moor J.A., Harland M., Williams S., Cuthbert-Heavens D., Sheridan E., Aveyard J., Sibley K., Whitaker L., Knowles M., Bishop J.N., Bishop D.T. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 2001, 10:55-62.
47. Laud K., Marian C., Avril M.F., Barrois M., Chompret A., Goldstein A.M., Tucker M.A., Clark P.A., Peters G., Chaudru V., Demenais F., Spatz A., Smith M.W., Lenoir G.M., Bressac-de Paillerets B. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J. Med. Genet. 2006, 43:39-47.
48. Hewitt C., Lee Wu C., Evans G., Howell A., Elles R.G., Jordan R., Sloan P., Read A.P., Thakker N. Germline mutation of ARF in a melanoma kindred. Hum. Mol. Genet. 2002, 11:1273-1279.
49. Nakamura M., Watanabe T., Klangby U., Asker C., Wiman K., Yonekawa Y., Kleihues P., Ohgaki H. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol. 2001, 11:159-168.
50. Rizos H., Puig S., Badenas C., Malvehy J., Darmanian A.P., Jimenez L., Mila M., Kefford R.F. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 2001, 20:5543-5547.
51. Robertson K.D., Jones P.A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell. Biol. 1998, 18:6457-6473.
52. Furonaka O., Takeshima Y., Awaya H., Ishida H., Kohno N., Inai K. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol. Int. 2004, 54:549-555.
53. Kominami K., Nagasaka T., Cullings H.M., Hoshizima N., Sasamoto H., Young J., Leggett B.A., Tanaka N., Matsubara N. Methylation in p14(ARF) is frequently observed in colorectal cancer with low-level microsatellite instability. J. Int. Med. Res. 2009, 37:1038-1045.
54. Konishi N., Nakamura M., Kishi M., Nishimine M., Ishida E., Shimada K. Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am. J. Pathol. 2002, 160:1207-1214.
55. Melendez B., Malumbres M., Perez de Castro I., Santos J., Pellicer A., Fernandez-Piqueras J. Characterization of the murine p19(ARF) promoter CpG island and its methylation pattern in primary lymphomas. Carcinogenesis 2000, 21:817-821.
56. Zemliakova V.V., Strel'nikov V.V., Zborovskaia I.B., Balukova O.V., Maiorova O.A., Vasil'ev E.V., Zaletaev D.V., Nemtsova M.V. Abnormal methylation of p16/CDKN2A AND p14/ARF genes GpG Islands in non-small cell lung cancer and in acute lymphoblastic leukemia. Mol. Biol. (Mosk) 2004, 38:966-972.
57. Zheng S., Chen P., McMillan A., Lafuente A., Lafuente M.J., Ballesta A., Trias M., Wiencke J.K. Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis 2000, 21:2057-2064.
58. Simon M., Park T.W., Koster G., Mahlberg R., Hackenbroch M., Bostrom J., Loning T., Schramm J. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J. Neurooncol 2001, 55:149-158.
59. Weihrauch M., Markwarth A., Lehnert G., Wittekind C., Wrbitzky R., Tannapfel A. Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver. Hum. Pathol. 2002, 33:884-892.
60. Vieth M., Schneider-Stock R., Rohrich K., May A., Ell C., Markwarth A., Roessner A., Stolte M., Tannapfel A. INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma. Virchows Arch. 2004, 445:135-141.
61. Dominguez G., Carballido J., Silva J., Silva J.M., Garcia J.M., Menendez J., Provencio M., Espana P., Bonilla F. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin. Cancer Res. 2002, 8:980-985.
62. Dominguez G., Silva J., Garcia J.M., Silva J.M., Rodriguez R., Munoz C., Chacon I., Sanchez R., Carballido J., Colas A., Espana P., Bonilla F. Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat. Res. 2003, 530:9-17.
63. Dominguez G., Silva J., Silva J.M., Garcia J.M., Larrondo F.J., Vargas J., Sanfrutos L., Provencio M., Espana P., Bonilla F. Different expression of P14ARF defines two groups of breast carcinomas in terms of TP73 expression and TP53 mutational status. Genes Chromosomes Cancer 2001, 31:99-106.
64. Silva J., Dominguez G., Silva J.M., Garcia J.M., Gallego I., Corbacho C., Provencio M., Espana P., Bonilla F. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene 2001, 20:4586-4590.
65. Silva J., Silva J.M., Dominguez G., Garcia J.M., Cantos B., Rodriguez R., Larrondo F.J., Provencio M., Espana P., Bonilla F. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J. Pathol. 2003, 199:289-297.
66. Nagy E., Beck Z., Kiss A., Csoma E., Telek B., Konya J., Olah E., Rak K., Toth F.D. Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur. J. Cancer 2003, 39:2298-2305.
67. Lind G.E., Thorstensen L., Lovig T., Meling G.I., Hamelin R., Rognum T.O., Esteller M., Lothe R.A. A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol. Cancer 2004, 3:28.
68. Lee M., Sup Han W., Kyoung Kim O., Hee Sung S., Sun Cho M., Lee S.N., Koo H. Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol. Res. Pract. 2006, 202:415-424.
69. Rousseau E., Ruchoux M.M., Scaravilli F., Chapon F., Vinchon M., De Smet C., Godfraind C., Vikkula M. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol. Appl. Neurobiol. 2003, 29:574-583.
70. Hashiguchi Y., Tsuda H., Yamamoto K., Inoue T., Ishiko O., Ogita S. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum. Pathol. 2001, 32:988-996.
71. Sarbia M., Geddert H., Klump B., Kiel S., Iskender E., Gabbert H.E. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int. J. Cancer 2004, 111:224-228.
72. Oh J.H., Kim H.S., Kim H.H., Kim W.H., Lee S.H. Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin. Orthop. Relat. Res. 2006, 442:216-222.
73. Nishimine M., Nakamura M., Kishi M., Okamoto M., Shimada K., Ishida E., Kirita T., Konishi N. Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. Oncol. Rep. 2003, 10:555-560.
74. Morris M.R., Hesson L.B., Wagner K.J., Morgan N.V., Astuti D., Lees R.D., Cooper W.N., Lee J., Gentle D., Macdonald F., Kishida T., Grundy R., Yao M., Latif F., Maher E.R. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 2003, 22:6794-6801.
75. Sherr C.J. An Arf(GFP/GFP) reporter mouse reveals that the Arf tumor suppressor monitors latent oncogenic signals in vivo. Cell Cycle 2004, 3:239-240.
76. Zindy F., Williams R.T., Baudino T.A., Rehg J.E., Skapek S.X., Cleveland J.L., Roussel M.F., Sherr C.J. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15930-15935.
77. Inoue K., Roussel M.F., Sherr C.J. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3993-3998.
78. Inoue K., Sherr C.J. Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol. Cell. Biol. 1998, 18:1590-1600.
79. Bodner S.M., Naeve C.W., Rakestraw K.M., Jones B.G., Valentine V.A., Valentine M.B., Luthardt F.W., Willman C.L., Raimondi S.C., Downing J.R., Roussel M.F., Sherr C.J., Look A.T. Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1). Gene 1999, 229:223-228.
80. Sreeramaneni R., Chaudhry A., McMahon M., Sherr C.J., Inoue K. Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol. Cell. Biol. 2005, 25:220-232.
81. Inoue K., Wen R., Rehg J.E., Adachi M., Cleveland J.L., Roussel M.F., Sherr C.J. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev. 2000, 14:1797-1809.
82. Inoue K., Mallakin A., Frazier D.P. Dmp1 and tumor suppression. Oncogene 2007, 26:4329-4335.
83. Miceli A.P., Saporita A.J., Weber J.D. Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint. Mol. Cell. Biol. 2011, 32:348-364.
84. Groth A., Weber J.D., Willumsen B.M., Sherr C.J., Roussel M.F. Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases. J. Biol. Chem. 2000, 275:27473-27480.
85. DiGiammarino E.L., Filippov I., Weber J.D., Bothner B., Kriwacki R.W. Solution structure of the p53 regulatory domain of the p19Arf tumor suppressor protein. Biochemistry 2001, 40:2379-2386.
86. Ozenne P., Eymin B., Brambilla E., Gazzeri S. The ARF tumor suppressor: structure, functions and status in cancer. Int. J. Cancer 2010, 127:2239-2247.
87. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 2006, 6:663-673.
88. Bertwistle D., Sugimoto M., Sherr C.J. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 2004, 24:985-996.
89. Kuo M.L., den Besten W., Bertwistle D., Roussel M.F., Sherr C.J. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 2004, 18:1862-1874.
90. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
91. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8424-8429.
92. Junttila M.R., Evan G.I. p53-a Jack of all trades but master of none. Nat. Rev. Cancer 2009, 9:821-829.
93. Chen J., Lin J., Levine A.J. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1995, 1:142-152.
94. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
95. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
96. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362:857-860.
97. Marine J.C., Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 2010, 17:93-102.
98. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378:206-208.
99. Soussi T., Wiman K.G. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007, 12:303-312.
100. Pomerantz J., Schreiber-Agus N., Liegeois N.J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.W., Cordon-Cardo C., DePinho R.A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998, 92:713-723.
101. Weber J.D., Kuo M.L., Bothner B., DiGiammarino E.L., Kriwacki R.W., Roussel M.F., Sherr C.J. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol. Cell. Biol. 2000, 20:2517-2528.
102. Weber J.D., Taylor L.J., Roussel M.F., Sherr C.J., Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1999, 1:20-26.
103. Lohrum M.A., Ashcroft M., Kubbutat M.H., Vousden K.H. Identification of a cryptic nucleolar-localization signal in MDM2. Nat. Cell Biol. 2000, 2:179-181.
104. Tao W., Levine A.J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6937-6941.
105. Efeyan A., Garcia-Cao I., Herranz D., Velasco-Miguel S., Serrano M. Tumour biology: policing of oncogene activity by p53. Nature 2006, 443:159.
106. Maggi L.B., Weber J.D. Nucleolar adaptation in human cancer. Cancer Invest. 2005, 23:599-608.
107. Leary D.J., Huang S. Regulation of ribosome biogenesis within the nucleolus. FEBS Lett. 2001, 509:145-150.
108. Thomas G. An encore for ribosome biogenesis in the control of cell proliferation. Nat. Cell Biol. 2000, 2:E71-E72.
109. Moss T., Langlois F., Gagnon-Kugler T., Stefanovsky V. A housekeeper with power of attorney: the rRNA genes in ribosome biogenesis. Cell. Mol. Life Sci. 2007, 64:29-49.
110. Sugimoto M., Kuo M.L., Roussel M.F., Sherr C.J. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 2003, 11:415-424.
111. Itahana K., Bhat K.P., Jin A., Itahana Y., Hawke D., Kobayashi R., Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 2003, 12:1151-1164.
112. Brady S.N., Yu Y., Maggi L.B., Weber J.D. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol. Cell. Biol. 2004, 24:9327-9338.
113. Yung B.Y., Busch R.K., Busch H., Mauger A.B., Chan P.K. Effects of actinomycin D analogs on nucleolar phosphoprotein B23 (37,000 daltons/pI 5.1). Biochem. Pharmacol. 1985, 34:4059-4063.
114. Spector D.L., Ochs R.L., Busch H. Silver staining, immunofluorescence, and immunoelectron microscopic localization of nucleolar phosphoproteins B23 and C23. Chromosoma 1984, 90:139-148.
115. Maggi L.B., Kuchenruether M., Dadey D.Y., Schwope R.M., Grisendi S., Townsend R.R., Pandolfi P.P., Weber J.D. Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome. Mol. Cell. Biol. 2008, 28:7050-7065.
116. Grisendi S., Mecucci C., Falini B., Pandolfi P.P. Nucleophosmin and cancer. Nat. Rev. Cancer 2006, 6:493-505.
117. Feuerstein N., Spiegel S., Mond J.J. The nuclear matrix protein, numatrin (B23), is associated with growth factor-induced mitogenesis in Swiss 3T3 fibroblasts and with T lymphocyte proliferation stimulated by lectins and anti-T cell antigen receptor antibody. J. Cell Biol. 1988, 107:1629-1642.
118. Boon K., Caron H.N., van Asperen R., Valentijn L., Hermus M.C., van Sluis P., Roobeek I., Weis I., Voute P.A., Schwab M., Versteeg R. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. Embo J. 2001, 20:1383-1393.
119. Zeller K.I., Haggerty T.J., Barrett J.F., Guo Q., Wonsey D.R., Dang C.V. Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation. J. Biol. Chem. 2001, 276:48285-48291.
120. Hingorani K., Szebeni A., Olson M.O. Mapping the functional domains of nucleolar protein B23. J. Biol. Chem. 2000, 275:24451-24457.
121. Borer R.A., Lehner C.F., Eppenberger H.M., Nigg E.A. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989, 56:379-390.
122. Szebeni A., Olson M.O. Nucleolar protein B23 has molecular chaperone activities. Protein Sci. 1999, 8:905-912.
123. Okuwaki M., Matsumoto K., Tsujimoto M., Nagata K. Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett. 2001, 506:272-276.
124. Tago K., Chiocca S., Sherr C.J. Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:7689-7694.
125. Saporita A.J., Chang H.C., Winkeler C.L., Apicelli A.J., Kladney R.D., Wang J., Townsend R.R., Michel L.S., Weber J.D. RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis. Cancer Res. 2011, 71:6708-6717.
126. Bleichert F., Baserga S.J. The long unwinding road of RNA helicases. Mol. Cell 2007, 27:339-352.
127. Lessard F., Morin F., Ivanchuk S., Langlois F., Stefanovsky V., Rutka J., Moss T. The ARF tumor suppressor controls ribosome biogenesis by regulating the RNA polymerase I transcription factor TTF-I. Mol. Cell 2010, 38:539-550.
128. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998, 12:2424-2433.
129. Qi Y., Gregory M.A., Li Z., Brousal J.P., West K., Hann S.R. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 2004, 431:712-717.
130. Amente S., Gargano B., Varrone F., Ruggiero L., Dominguez-Sola D., Lania L., Majello B. p14ARF directly interacts with Myc through the Myc BoxII domain. Cancer Biol. Ther. 2006, 5:287-291.
131. Amente S., Gargano B., Diolaiti D., Della Valle G., Lania L., Majello B. p14(ARF) interacts with N-Myc and inhibits its transcriptional activity. FEBS Lett. 2007, 581:821-825.
132. Datta A., Nag A., Pan W., Hay N., Gartel A.L., Colamonici O., Mori Y., Raychaudhuri P. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J. Biol. Chem. 2004, 279:36698-36707.
133. Zhu J.W., DeRyckere D., Li F.X., Wan Y.Y., DeGregori J. A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection. Cell Growth Differ. 1999, 10:829-838.
134. Dimri G.P., Itahana K., Acosta M., Campisi J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol. Cell. Biol. 2000, 20:273-285.
135. Eymin B., Karayan L., Seite P., Brambilla C., Brambilla E., Larsen C.J., Gazzeri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001, 20:1033-1041.
136. Martelli F., Hamilton T., Silver D.P., Sharpless N.E., Bardeesy N., Rokas M., DePinho R.A., Livingston D.M., Grossman S.R. p19ARF targets certain E2F species for degradation. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4455-4460.
137. Datta A., Nag A., Raychaudhuri P. Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol. Cell. Biol. 2002, 22:8398-8408.
138. Datta A., Sen J., Hagen J., Korgaonkar C.K., Caffrey M., Quelle D.E., Hughes D.E., Ackerson T.J., Costa R.H., Raychaudhuri P. ARF directly binds DP1: interaction with DP1 coincides with the G1 arrest function of ARF. Mol. Cell. Biol. 2005, 25:8024-8036.
139. Komori H., Enomoto M., Nakamura M., Iwanaga R., Ohtani K. Distinct E2F-mediated transcriptional program regulates p14ARF gene expression. Embo J. 2005, 24:3724-3736.
140. Ayrault O., Andrique L., Fauvin D., Eymin B., Gazzeri S., Seite P. Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene 2006, 25:7577-7586.
141. Karayan L., Riou J.F., Seite P., Migeon J., Cantereau A., Larsen C.J. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 2001, 20:836-848.
142. Costa R.H., Kalinichenko V.V., Major M.L., Raychaudhuri P. New and unexpected: forkhead meets ARF. Curr. Opin. Genet. Dev. 2005, 15:42-48.
143. Costa R.H., Kalinichenko V.V., Holterman A.X., Wang X. Transcription factors in liver development, differentiation, and regeneration. Hepatology 2003, 38:1331-1347.
144. Wang X., Hung N.J., Costa R.H. Earlier expression of the transcription factor HFH-11B diminishes induction of p21(CIP1/WAF1) levels and accelerates mouse hepatocyte entry into S-phase following carbon tetrachloride liver injury. Hepatology 2001, 33:1404-1414.
145. Ye H., Holterman A.X., Yoo K.W., Franks R.R., Costa R.H. Premature expression of the winged helix transcription factor HFH-11B in regenerating mouse liver accelerates hepatocyte entry into S phase. Mol. Cell. Biol. 1999, 19:8570-8580.
146. Kalinichenko V.V., Major M.L., Wang X., Petrovic V., Kuechle J., Yoder H.M., Dennewitz M.B., Shin B., Datta A., Raychaudhuri P., Costa R.H. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004, 18:830-850.
147. Kawagishi H., Nakamura H., Maruyama M., Mizutani S., Sugimoto K., Takagi M., Sugimoto M. ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA. Cancer Res. 2010, 70:4749-4758.
148. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
149. Kuchenreuther M.J., Weber J.D. Translational Control of Drosha by the ARF Tumor Suppressor 2012, (In Submission).
150. Apicelli A.J., Maggi L.B., Hirbe A.C., Miceli A.P., Olanich M.E., Schulte-Winkeler C.L., Saporita A.J., Kuchenreuther M., Sanchez J., Weilbaecher K., Weber J.D. A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function. Mol. Cell. Biol. 2008, 28:1068-1080.
151. Pich A., Chiusa L., Margaria E. Prognostic relevance of AgNORs in tumor pathology. Micron 2000, 31:133-141.
152. Pelletier C.L., Maggi L.B., Brady S.N., Scheidenhelm D.K., Gutmann D.H., Weber J.D. TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation. Cancer Res. 2007, 67:1609-1617.
153. Yu Y., Maggi L.B., Brady S.N., Apicelli A.J., Dai M.S., Lu H., Weber J.D. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol. Cell. Biol. 2006, 26:3798-3809.
154. McKeller R.N., Fowler J.L., Cunningham J.J., Warner N., Smeyne R.J., Zindy F., Skapek S.X. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3848-3853.
155. Ito M., Yoshioka M. Regression of the hyaloid vessels and pupillary membrane of the mouse. Anat. Embryol. (Berl) 1999, 200:403-411.
156. Goldberg M.F. Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 1997, 124:587-626.
157. Haddad R., Font R.L., Reeser F. Persistent hyperplastic primary vitreous. A clinicopathologic study of 62 cases and review of the literature. Surv. Ophthalmol. 1978, 23:123-134.
158. Gromley A., Churchman M.L., Zindy F., Sherr C.J. Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6285-6290.
159. Cole F., Keeney S., Jasin M. Evolutionary conservation of meiotic DSB proteins: more than just Spo11. Genes Dev. 2010, 24:1201-1207.
160. Churchman M.L., Roig I., Jasin M., Keeney S., Sherr C.J. Expression of arf tumor suppressor in spermatogonia facilitates meiotic progression in male germ cells. PLoS Genet. 2011, 7:e1002157.
161. Inagaki A., Schoenmakers S., Baarends W.M. DNA double strand break repair, chromosome synapsis and transcriptional silencing in meiosis. Epigenetics. 2010, 5:255-266.
162. Mahadevaiah S.K., Turner J.M., Baudat F., Rogakou E.P., de Boer P., Blanco-Rodriguez J., Jasin M., Keeney S., Bonner W.M., Burgoyne P.S. Recombinational DNA double-strand breaks in mice precede synapsis. Nat. Genet. 2001, 27:271-276.